NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Phase 2/3 Study of Brepocitinib in Adults With Cutaneous Sarcoidosis

RecruitingPhase 2, Phase 3

Sponsor: Priovant Therapeutics, Inc.

Conditions: Cutaneous Sarcoidosis

Interventions: Oral Brepocitinib, Oral Placebo

Countries: United States

This study will evaluate the clinical safety and efficacy of oral brepocitinib in participants with cutaneous sarcoidosis.

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: INTERVENTIONAL

Eligibility criteria

Inclusion Criteria:

1. Adults subjects
2. Cutaneous sarcoidosis with characteristic skin biopsy histology
3. A CSAMI activity score ≥ 10
4. Weight \> 40 kg to \< 130 kg, and with a body mass index (BMI) ≤ 45 kg/m2.

Exclusion Criteria

1. History of cancer, with the exception of the following cancers with documentation of complete resection and no evidence of recurrence for ≥ 1 year: basal cell carcinoma, squamous cell carcinoma, or carcinoma in situ of the uterine cervix.
2. High risk of thrombosis or cardiovascular disease
3. High risk of herpes zoster
4. Active or recent infection

Locations (4)

San Francisco, California, United States
Durham, North Carolina, United States
Philadelphia, Pennsylvania, United States
Madison, Wisconsin, United States